P. Steg

发表

Universal definition of myocardial infarction

Spain, E. Antman, S. Priori, 2007 .

Universal definition of myocardial infarction

Spain, E. Antman, J. Alpert, 2007 .

Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

L. Deckelbaum, P. Ridker, S. Pocock, 2020, American heart journal.

Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".

K. Mahaffey, L. Wallentin, D. Wojdyla, 2014, Circulation.

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

L. Wallentin, R. Harrington, H. Katus, 2013, JACC. Cardiovascular interventions.

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry

J. Ferrières, P. Steg, N. Danchin, 2011, Circulation.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

B. J. Barratt, L. Wallentin, R. Becker, 2010, The Lancet.

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology ( ESC )

K. Mahaffey, A. Budaj, J. Knuuti, 2012 .

Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).

J. Tardif, R. Ferrari, M. Tendera, 2011, The American journal of cardiology.

Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT

J. Tardif, C. Ballantyne, E. Brinton, 2019 .

Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy.

Sunil V. Rao, B. Lewis, R. Giugliano, 2013, American heart journal.

News from the European Society of Cardiology congress in Vienna, August 30 to September 3, 2003.

O. Smiseth, K. Sipido, A. Battler, 2004, Journal of the American College of Cardiology.

Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris.

E. Vicaut, H. Benamer, J. Bénessiano, 1998, The American journal of cardiology.

Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

C. Held, C. Cannon, H. White, 2017, Journal of the American Heart Association.

Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial

G. Abecasis, E. Hagström, G. Yancopoulos, 2019, Circulation.

Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina.

E. Vicaut, L. Feldman, H. Benamer, 1999, American heart journal.

The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE).

J. Gore, A. Yan, S. Goodman, 2012, The Canadian journal of cardiology.

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

E. Braunwald, B. Scirica, R. Frederich, 2014, Circulation.

Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)

S. Pocock, T. Henry, M. Krucoff, 2018, Circulation. Cardiovascular interventions.

Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronarySyndrome

M. Szarek, A. Moryusef, R. Pordy, 2022 .

Immediate vs Delayed Intervention for Acute Coronary Syndromes

G. Montalescot, J. Collet, J. Silvain, 2013 .

P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.

E. Ohman, F. Rockhold, T. Povsic, 2019, JAMA cardiology.

Pre-treatment with a P2Y12 antagonist before PCI in STEMI: why should we wait?

P. Steg, P. Steg, J. Abtan, 2019, European heart journal.

Incidence ,

S. Pocock, T. Henry, M. Krucoff, 2018 .

Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".

B. Lewis, K. Mahaffey, B. Meier, 2014, Circulation.

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines

S. Yusuf, C. Granger, D. Faxon, 2013 .

Lipoprotein(a) and Benefit of Antiplatelet Therapy

Marc P. Bonaca, M. O’Donoghue, P. Jarolím, 2023, JACC. Advances.

Comparison of Thrombolysis Followed by Broad Use of Percutaneous Coronary Intervention With Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Acute Myocardial Infarction Data From the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI) Interventional Cardiology

T. Simon, P. Asseman, J. Cambou, 2008 .

Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.

J. Kastelein, A. Lincoff, R. Mehran, 2016, American heart journal.